Literature DB >> 9774399

Mutation at histidine 338 of gp91(phox) depletes FAD and affects expression of cytochrome b558 of the human NADPH oxidase.

L S Yoshida1, F Saruta, K Yoshikawa, O Tatsuzawa, S Tsunawaki.   

Abstract

Defective NADPH oxidase components prevent superoxide (O-2) generation, causing chronic granulomatous disease (CGD). X-linked CGD patients have mutations in the gene encoding the gp91(phox) subunit of cytochrome b558 and usually lack gp91(phox) protein completely (X91(0)). gp91(phox) is considered to be a flavocytochrome that contains binding sites for NADPH, FAD, as well as heme. We here report a rare X-linked CGD patient whose neutrophils entirely failed to produce O-2, but presented a diminished expression of gp91(phox) containing about one-third of the heme present in normal individuals by Soret absorption. Translocation of cytosolic factors p67(phox) and p47(phox) was normal. However, the FAD content in his neutrophil membranes was as low as that of X91(0) patients, suggesting complete depletion of FAD in his gp91(phox). This was in agreement with the finding that a single base substitution (C1024 to T) changed His-338 to Tyr in gp91(phox) in a predicted FAD-binding domain of the flavocytochrome model. The loss of FAD could not be corrected even after addition of reagent FAD or a FAD-rich dehydrogenase fraction isolated from normal neutrophils to the patient's membranes, in a reconstitution in vitro with normal cytosol. These results indicate that His-338 is a very critical residue for FAD incorporation into the NADPH oxidase system. This is the first such mutation found in CGD.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9774399     DOI: 10.1074/jbc.273.43.27879

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  14 in total

Review 1.  Hematologically important mutations: X-linked chronic granulomatous disease (third update).

Authors:  Dirk Roos; Douglas B Kuhns; Anne Maddalena; Joachim Roesler; Juan Alvaro Lopez; Tadashi Ariga; Tadej Avcin; Martin de Boer; Jacinta Bustamante; Antonio Condino-Neto; Gigliola Di Matteo; Jianxin He; Harry R Hill; Steven M Holland; Caroline Kannengiesser; M Yavuz Köker; Irina Kondratenko; Karin van Leeuwen; Harry L Malech; László Marodi; Hiroyuki Nunoi; Marie-José Stasia; Anna Maria Ventura; Carl T Witwer; Baruch Wolach; John I Gallin
Journal:  Blood Cells Mol Dis       Date:  2010-08-21       Impact factor: 3.039

2.  Fungal metabolite gliotoxin targets flavocytochrome b558 in the activation of the human neutrophil NADPH oxidase.

Authors:  Satoshi Nishida; Lucia S Yoshida; Takashi Shimoyama; Hiroyuki Nunoi; Toshihiro Kobayashi; Shohko Tsunawaki
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

3.  Role of putative second transmembrane region of Nox2 protein in the structural stability and electron transfer of the phagocytic NADPH oxidase.

Authors:  Antoine Picciocchi; Franck Debeurme; Sylvain Beaumel; Marie-Claire Dagher; Didier Grunwald; Algirdas J Jesaitis; Marie-José Stasia
Journal:  J Biol Chem       Date:  2011-06-09       Impact factor: 5.157

Review 4.  Nox NADPH oxidases and the endoplasmic reticulum.

Authors:  Francisco R M Laurindo; Thaís L S Araujo; Thalita B Abrahão
Journal:  Antioxid Redox Signal       Date:  2014-02-26       Impact factor: 8.401

5.  Residual NADPH oxidase and survival in chronic granulomatous disease.

Authors:  Douglas B Kuhns; W Gregory Alvord; Theo Heller; Jordan J Feld; Kristen M Pike; Beatriz E Marciano; Gulbu Uzel; Suk See DeRavin; Debra A Long Priel; Benjamin P Soule; Kol A Zarember; Harry L Malech; Steven M Holland; John I Gallin
Journal:  N Engl J Med       Date:  2010-12-30       Impact factor: 91.245

6.  Inhibition of the neutrophil NADPH oxidase and associated H+ channel by diethyl pyrocarbonate (DEPC), a histidine-modifying agent: evidence for at least two target sites.

Authors:  T J Mankelow; L M Henderson
Journal:  Biochem J       Date:  2001-09-01       Impact factor: 3.857

7.  Characterization of six novel mutations in the CYBB gene leading to different sub-types of X-linked chronic granulomatous disease.

Authors:  Marie José Stasia; Pierre Bordigoni; Daniel Floret; Jean Paul Brion; Cécile Bost-Bru; Gérard Michel; Pierre Gatel; Denis Durant-Vital; Marie Antoinette Voelckel; Xing Jun Li; Michèle Guillot; Elisabeth Maquet; Cécile Martel; Françoise Morel
Journal:  Hum Genet       Date:  2004-11-06       Impact factor: 4.132

8.  Variant Type X91+ Chronic Granulomatous Disease: Clinical and Molecular Characterization in a Chinese Cohort.

Authors:  Bijun Sun; Zeyu Zhu; Xiaoying Hui; Jinqiao Sun; Wenjie Wang; Wenjing Ying; Qinhua Zhou; Haili Yao; Jia Hou; Xiaochuan Wang
Journal:  J Clin Immunol       Date:  2022-07-07       Impact factor: 8.317

9.  Gp91phox (NOX2) in classically activated microglia exacerbates traumatic brain injury.

Authors:  Kenji Dohi; Hirokazu Ohtaki; Tomoya Nakamachi; Sachiko Yofu; Kazue Satoh; Kazuyuki Miyamoto; Dandan Song; Shohko Tsunawaki; Seiji Shioda; Tohru Aruga
Journal:  J Neuroinflammation       Date:  2010-07-26       Impact factor: 8.322

10.  Constitutive NADPH-dependent electron transferase activity of the Nox4 dehydrogenase domain.

Authors:  Yukio Nisimoto; Heather M Jackson; Hisamitsu Ogawa; Tsukasa Kawahara; J David Lambeth
Journal:  Biochemistry       Date:  2010-03-23       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.